Solid-State Characterization and Dissolution Properties of Lovastatin Hydroxypropyl-β-Cyclodextrin Inclusion Complex - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Solid-State Characterization and Dissolution Properties of Lovastatin Hydroxypropyl-β-Cyclodextrin Inclusion Complex
The objectives of this study were to prepare and characterize inclusion complexes of lovastatin with hydroxypropyl-β-cyclodextrin (HPβ-CD) and to study the effect of the complexes on the dissolution rate of lovastatin (LVS). The findings suggest that LVS's poor dissolution profile can be overcome by preparing its inclusion complex with HPβ-CD.


Pharmaceutical Technology


11. J. Peeters et al., "Characterization of the Interaction of 2-Hydroxypropyl-Betacyclodextrin with Itraconazole at pH 2, 4, and 7," J. Pharm. Sci . 91 (66), 1414–1422 (2002).

12. F. J. Veiga et al., "Molecular Modeling and 1H-NMR: Ultimate Tools for the Investigation of Tolbutamide: β-Cyclodextrin and Tolbutamide: Hydroxypropyl-β-Cyclodextrin Complexes," Chem. Pharm. Bull. (Tokyo). 49 (10), 1251–1256 (2001).

13. J. Szejtli, "Medicinal Applications of Cyclodextrins," Med. Res. Rev. 14 (3), 353–386 (1994).

14. J.W. Moore and H. Flanner, "Mathematical Comparison of Dissolution Profiles," Pharm. Technol. 20 (6), 64–74 (1996).

15. US Food and Drug Administration, Guidance for Industry SUPAC-MR: Modified Release Solid Oral Dosage Forms Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls; In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation (FDA, Rockville, MD, 1997).

16. Human Medicines Evaluation Unit, European Agency for the Evaluation of Medicinal Products (EMEA), Notes for Guidance on Quality of Modified-Release Products; A Oral Dosage Forms; B Transdermal Dosage Forms, Section 1 (Quality) (EMEA, London, UK, 1999).

17. C. Reppas and E. Nicolaides, "Analysis of Drug Dissolution Data," in Oral Drug Absorption Prediction and Assessment, J.B. Dressman and H. Lennernäs, Eds. (Marcel Dekker, Inc., New York, NY, 2000), pp. 229–254.

18. M.L. Vueba et al.,"Influence of Cellulose Ether Polymers on Ketoprofen Release from Hydrophilic Matrix Tablets," Eur. J. Pharm. and Biopharm. 58 (1), 51–59 (2004).

19. T. Higuchi and K. Connors, "Phase Solubility Techniques," in Advances in Analytical Chemistry and Instrumention, C.N. Reilly, Ed. (John Wiley, New York, NY, 1965) 4, 117–212.

20. S. Mattsson and C. Nyström, "The Use of Mercury Porosimetry in Assessing the Effect of Different Binders on the Pore Structure and Bonding Properties of Tablets," Eur. J. Pharm. Biopharm. 52 (2), 237–247 (2001).

21. K. Kawakita, "Compression of Powder," Kagaku . 26, 149–150 (1956).

22. R.L. Carr, "Evaluating Flow Properties of Solids," Chem. Eng. 72 (2), 163–168 (1965).

23. D. Peri et al.,"Inclusion Complexes of Tolnaftate with β-Cyclodextrin and Hydroxy-β-Cyclodextrin," Drug Dev. Ind. Pharm. 20 (88), 1401–1410 (1994).

24. J.J.T. Labenderia et al., "Glibornuride-β-Cyclodextrin Inclusion Complexes: Preparation, Structural Characterization, and In Vitro Dissolution Behavior," Eur. J. Pharm. and Biopharm. 39 (6), 255–259 (1993).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
29%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
13%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here